Anna F. Farago, MD, PhD

Articles by Anna F. Farago, MD, PhD

Dr. Anna F. Farago New Cytotoxic Strategies for Relapsed Small-Cell Lung Cancer

ByAnna F. Farago, MD, PhD

June 12th 2019

Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC

ByAnna F. Farago, MD, PhD

June 11th 2019

Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.

Latest Updated Articles

Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC
June 11th 2019
Dr. Anna F. Farago New Cytotoxic Strategies for Relapsed Small-Cell Lung Cancer
June 12th 2019

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)